Associated Papers
CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study.
Chan ER et al.
Pharmacogenomics, 2022
Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes.
Hongkaew Y et al.
Pharmacogenomics, 2021
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X et al.
Bmc Infectious Diseases, 2019
Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing.
Buermans HP et al.
Human Mutation, 2017
28044414 (PubMed )
Supplement: HUMU-38-310-s004.xlsx › Sup_Table_3
Genetic polymorphisms analysis of CYP2D6 in the Uygur population.
He X et al.
Bmc Genomics, 2016
Effects of 22 CYP2D6 Genetic Variations Newly Identified in Chinese Population on Olanzapine Metabolism in vitro.
Zhou HY et al.
Pharmacology, 2016
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX et al.
Drug Metabolism Reviews, 2015
CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping.
Riffel AK et al.
Frontiers in Pharmacology, 2015
Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
Jin TB et al.
Gene, 2013
Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.
Wright GE et al.
Annals of Human Genetics, 2010
Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans.
Lee SJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.
Matimba A et al.
Human Genomics, 2009
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clinical Pharmacokinetics, 2009
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C et al.
Pharmacogenetics and Genomics, 2006
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Toscano C et al.
Pharmacogenetics and Genomics, 2006
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Raimundo S et al.
Clinical Pharmacology and Therapeutics, 2004
Select a paper to view details